

GUEST EDITORS' PAGE



# Translating Cardioprotection for Patient Benefit

## The EU-CARDIOPROTECTION COST Action



Derek J. Hausenloy, MD,<sup>a,b</sup> Gerd Heusch, MD<sup>c</sup>

Acute myocardial infarction and the subsequent development of heart failure are among the leading causes of death and disability globally. The most effective treatment for limiting infarct size and preventing subsequent heart failure is timely interventional or surgical reperfusion, but even then, mortality and morbidity remain significant (1). Accordingly, new treatments are required, but the translation of adjunct cardioprotection to clinical practice has been largely disappointing so far (2). Reasons for such poor translation and novel strategies are addressed in the ongoing European Union (EU)-CARDIOPROTECTION Cooperation in Science and Technology (COST) Action (CA16225).

Since 1971, the EU COST has led and supported transnational cooperation across Europe. It provides 4 years of funding for the creation of research networks (COST Actions) and funds workshops, conferences, training schools, short-term scientific missions, and dissemination activities. COST Actions offer a multidisciplinary platform for collaboration among scientists across Europe (and beyond) and facilitate advancements in research and innovation. The EU-CARDIOPROTECTION COST Action comprises

a research network of 32 EU countries, whose overall research objective is to improve the translation of cardioprotection from the experimental setting to the clinical arena. It is organized into 4 working groups with specific research aims (Figure 1):


### WORKING GROUP 1: NEW TARGETS

COST Action aims to identify novel signaling pathways and therapeutic targets of cardioprotection both within and outside of the cardiomyocyte. There is a series of papers in a Cardiovascular Research Spotlight Issue, "Cardioprotection Beyond the Cardiomyocyte," which highlight noncardiomyocyte targets, such as the coronary circulation (3), immune cells (4), innate immunity (5), circulating hematopoietic cells and extracellular vesicles (6), and the cardiac innervation (7). Whereas many experimental studies rely on a reductionist strategy focused on a single signaling pathway or target, the working group aims to use innovative unbiased multi-omics strategies and network bioinformatics analyses to identify new signaling pathways and targets for cardioprotection.

### WORKING GROUP 2: COMBINATION THERAPY

Most experimental cardioprotection studies have been directed to one particular signaling pathway or target. However, acute myocardial infarction is a complex phenomenon that involves not only cardiomyocytes, but also coronary microvasculature, nerves, immune and circulating blood cells, and extracellular vesicles. Working group 2 aims to identify multitarget therapies directed to multiple signaling pathways and end-effectors both within and

From <sup>a</sup>The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London, United Kingdom; <sup>b</sup>Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore; and the <sup>c</sup>Institute for Pathophysiology, West German Heart and Vascular Centre, University of Essen Medical School, Essen, Germany. Dr. Hausenloy is the chair and Dr. Heusch is one of the Working Group leaders of the European Cooperation in Science and Technology (COST Action CA16225, EU-Cardioprotection). Dr. Hausenloy is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. Dr. Heusch is supported by the German Research Foundation (SFB 1116 B8).



outside the cardiomyocyte that can be used in combination to achieve additive and/or synergistic cardioprotective effects. A road map for synergistic multitarget therapies as a more effective strategy for translating cardioprotection to patient benefit has just been published in the *Journal* (8).

### WORKING GROUP 3: CONFOUNDERS

Experimental studies mostly use healthy and young animal models with acute coronary ligation, whereas most patients experiencing myocardial infarction are middle-aged or elderly, have comorbidities (such as diabetes, hyperlipidemia, hypertension), and are on multiple medications, all of which may affect the efficacy of cardioprotection (9). Working group 3 aims to identify key comorbidities and comedications that

affect cardioprotection and the mechanisms underlying their interference.

### WORKING GROUP 4: CONSORTIUM

Most cardioprotective therapies that have failed in the clinical setting did not provide robust cardioprotection in the experimental setting. This lack of robustness is attributed to methodological limitations such as lack of randomization, nonblinded treatment allocation and data analysis, failure to standardize acute myocardial ischemia and reperfusion protocols, and lack of rigor in statistical analysis. Working group 4 has provided a detailed cookbook of practical guidelines to improve rigor and reproducibility of experimental and clinical cardioprotection studies (10). Eventually, a European Cardioprotection

Consortium for multicenter experimental testing of novel cardioprotective therapies in a randomized controlled and blinded manner, using clinically relevant small/large animal acute myocardial infarction models will be set up, in part following the National Institutes of Health-sponsored CAESAR network.

### COST ACTION NETWORKING ACTIVITIES

**Figure 1** provides an overview of the EU-CARDIOPROTECTION COST Action CA16225 organization and activities.

- **Scientific Meetings:** Biannual scientific meetings have been held in Brussels, Vienna, Santorini, and Kragujevac to provide a forum for COST members and others to disseminate and share knowledge pertinent to cardioprotection. Leading researchers from Europe and worldwide have been invited to provide their expert input.
- **Training Schools:** Training schools are organized on topics relevant to cardioprotection research, such as multi-omics strategies and choice of clinically relevant animal models with comorbidities and comedication. In 2019, COST Action will participate in the European Society of Cardiology Council of Basic Cardiovascular Science Summer School by organizing sessions relevant to cardioprotection.
- **Short-Term Scientific Missions:** COST Action has so far funded 20 early career investigators to learn

new research techniques and gain valuable knowledge and research experience in other European partner laboratories.

- **Communication and Dissemination Activities:** COST Action communicates its activities through its website (11). Working groups have published original papers, reviews, and position papers. COST Action has sponsored joint scientific sessions relevant to cardioprotection at the International Society of Heart Research-European Section annual scientific meeting.
- **Conference Grants:** These grants enable PhD students and early career investigators from less research-intensive European partner countries to attend international conferences to present their research.

In summary, COST Action has put in place a pan-European research network of leading experts and young investigators in cardioprotection to develop new strategies for finding innovative and more effective approaches to cardioprotection, so as to improve their translation for patient benefit.

---

**ADDRESS FOR CORRESPONDENCE:** Prof. Dr.med. Dr.h.c. Gerd Heusch, Institute for Pathophysiology, West German Heart and Vascular Center, University of Essen Medical School, Hufelandstrasse 55, Essen 45122, Germany. E-mail: [Gerd.Heusch@uk-essen.de](mailto:Gerd.Heusch@uk-essen.de). Twitter: [@unidue](https://twitter.com/unidue).

### REFERENCES

1. Hausenloy DJ, Bøtker HE, Engstrom T, et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. *Eur Heart J* 2017;38:935-41.
2. Heusch G. Critical issues for the translation of cardioprotection. *Circ Res* 2017;120:1477-86.
3. Hausenloy DJ, Chilian W, Crea F, et al. The coronary circulation in acute myocardial ischaemia/reperfusion injury—a target for cardioprotection. *Cardiovasc Res* 2018 Nov 14 [E-pub ahead of print].
4. Andreadou I, Cabrera-Fuentes HA, Devaux Y, et al. Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. *Cardiovasc Res* 2019 Mar 2 [E-pub ahead of print].
5. Zuurbier CJ, Abbate A, Cabrera-Fuentes HA, et al. Innate immunity as a target for acute cardioprotection. *Cardiovasc Res* 2018 Dec 21 [E-pub ahead of print].
6. Davidson SM, Andreadou I, Barile L, et al. Circulating blood cells and extracellular vesicles in acute cardioprotection. *Cardiovasc Res* 2018 Dec 24 [E-pub ahead of print].
7. Hausenloy DJ, Bøtker HE, Ferdinandy P, et al. Cardiac innervation in acute myocardial ischaemia/reperfusion injury and cardioprotection. *Cardiovasc Res* 2019 Feb 23 [E-pub ahead of print].
8. Davidson SM, Ferdinandy P, Andreadou I, et al. Multitarget strategies to reduce myocardial ischemia/reperfusion injury. *J Am Coll Cardiol* 2019;73:89-99.
9. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of risk factors, comorbidities and comedication with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. *Pharmacol Rev* 2014;66:1142-74.
10. Bøtker HE, Hausenloy D, Andreadou I, et al. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. *Basic Res Cardiol* 2018;113:39.
11. EU-CARDIOPROTECTION. Available at: [www.cardioprotection.eu](http://www.cardioprotection.eu). Accessed March 31, 2019.